MGLL and neoplasm: By inhibiting MAGL, 2-AG levels are increased in tumor cells and in tumor niches, leading to changes in immune cell behavior in the TME and resulting in altered immune cell profile within the tumor niches being shifted from pro-inflammatory profile to a more anti-tumorigenic profile41.